A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis
Phase of Trial: Phase IV
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Proof of concept
- 25 Apr 2017 Planned End Date changed from 1 Jul 2017 to 30 Jun 2018.
- 25 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 30 Dec 2017.
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.